Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Shoko Furukawa, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2018-99-114355

Published: 2018

Journal Articles

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Kenichi Ogiwara, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Mariko Noguchi-Sasaki, PhD, Tetsuhiro Soeda, PhD, Naoki Matsumoto, PhD, Michinori Hirata, PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2018-99-118504

Published: 2018

Journal Articles

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

Koji Yada, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Midori Shima, MDPhD

Blood (2017) 130 (Supplement 1): 3658.

https://doi.org/10.1182/blood.V130.Suppl_1.3658.3658

Published: 2017

Journal Articles

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yuka Tabuchi, Tetsuhiro Soeda, PhD, Nobuo Arai, Takehisa Kitazawa, Hidenari Takaoka, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1388.

https://doi.org/10.1182/blood.V128.22.1388.1388

Published: 2016

Journal Articles

Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)

Takashi Ishihara, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yasufumi Takeshita, MD, Akitaka Nomura, MD, Satoshi Ochi, MD, Toshiaki Ishida, MD PhD, Yoshiyuki Kosaka, MD PhD, Akihisa Sawada, PhD MD, Masami Inoue, MD, Midori Shima, MD PhD

Blood (2016) 128 (22): 5156.

https://doi.org/10.1182/blood.V128.22.5156.5156

Published: 2016

Journal Articles

Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 3565.

https://doi.org/10.1182/blood.V126.23.3565.3565

Published: 2015

Journal Articles

Activated Protein C-Catalyzed Factor Va Inactivation Predominantly Contributes to the Downregulation of Coagulation Rather Than Factor VIIIa Inactivation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 4222.

https://doi.org/10.1182/blood.V124.21.4222.4222

Published: 2014

Journal Articles

Factor VIII A2 Domain Contains a Binding Site for Factor X

Masahiro Takeyama, MD PhD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 4226.

https://doi.org/10.1182/blood.V124.21.4226.4226

Published: 2014

Journal Articles

Distinct Localization of Coagulation Factor VIII, Von Willebrand Factor and Factor VIIIa-Mimetic Bispecific Antibody Contributing to Thrombus Formation Under Whole Blood Flow Conditions

Yasuaki Shida, MD PhD, Keiji Nogami, MD PhD, Hiroaki Minami, MD, Hiroaki Yaoi, MD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2014) 124 (21): 1483.

https://doi.org/10.1182/blood.V124.21.1483.1483

Published: 2014

Journal Articles

Novel FV mutation (W1920R, FV Nara ) associated with serious deep vein thrombosis and more potent APC resistance relative to FV Leiden

Keiji Nogami, Keiko Shinozawa, Kenichi Ogiwara, Tomoko Matsumoto, Kagehiro Amano, Katsuyuki Fukutake, Midori Shima

Blood (2014) 123 (15): 2420–2428.

https://doi.org/10.1182/blood-2013-10-530089

Published: 2014

Journal Articles

An Optimal Monitoring On Bypassing Therapy for Hemophilia A Patients with Inhibitor Using aPTT-Based Clot Waveform Analysis with the Presence of Minimal TF

Junka Haku, MD, Kenichi Ogiwara, MD, PhD, Tomoko Matsumoto, PhD, Koji Yada, MD, Midori Shima, MD, PhD, Keiji Nogami, MD, PhD

Blood (2012) 120 (21): 3382.

https://doi.org/10.1182/blood.V120.21.3382.3382

Published: 2012

Journal Articles

Coagulation Functions with Clinical Phenotype and Inhibitory Mechanisms in Acquired Factor V Inhibitors.

Tomoko Matsumoto, PhD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2232.

https://doi.org/10.1182/blood.V120.21.2232.2232

Published: 2012

Journal Articles

Total-Thrombus-Formation Analysis System Using a Microchip Flow Chamber Reflects Bleeding Severity of Patients with Type 1 Von Willebrand Disease.

Kenichi Ogiwara, MD, PhD, Keiji Nogami, MD, PhD, Tomoko Matsumoto, PhD, Shoko Furukawa, MD, Hiroaki Minami, MD, Kazuya Hosokawa, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2237.

https://doi.org/10.1182/blood.V120.21.2237.2237

Published: 2012

Journal Articles

Mechanism of the Potent Activated Protein C Resistance of Novel Factor V Mutation with W1920R (FV Nara) Relative to R506Q (FV Leiden)

Kenichi Ogiwara, MD, PhD, Keiko Shinozawa, PhD, Keiji Nogami, MD, PhD, Tomoko Matsumoto, Katsumi Nishiya, MD, PhD, Nobuyuki Tsujii, MD, Koji Yada, MD, Katsuyuki Fukutake, MD, PhD, Midori Shima, MD, PhD

Blood (2011) 118 (21): 537.

https://doi.org/10.1182/blood.V118.21.537.537

Published: 2011

Journal Articles

Pharmacokinetics of Continuous Infusion Therapy of Factor VIII Concentrates in Hemophilia A Patients with Inhibitors,

Katsumi Nishiya, MD, PhD, Ichiro Tanaka, MD, PhD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Koji Yada, MD, Tomoko Matsumoto, Midori Shima, MD, PhD

Blood (2011) 118 (21): 3320.

https://doi.org/10.1182/blood.V118.21.3320.3320

Published: 2011

Journal Articles

Evaluation of Comprehensive Hemostatic Function of Patients with Von Willebrand Disease (VWD) Under Flow Using a New Microchip Flow Chamber System

Kenichi Ogiwara, MD, PhD, Kazuya Hosokawa, PhD, Keiji Nogami, MD, PhD, Tomoko Matsumoto, Midori Shima, MD, PhD

Blood (2011) 118 (21): 2283.

https://doi.org/10.1182/blood.V118.21.2283.2283

Published: 2011

Journal Articles

Determination of Coagulation Functions and Inhibitory Mechanisms In Acquired Hemophilia A with Type 1 and Type 2 Inhibitors.

Tomoko Matsumoto, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, Nobuyuki Tsujii, MD, Midori Shima, MD, PhD

Blood (2010) 116 (21): 3666.

https://doi.org/10.1182/blood.V116.21.3666.3666

Published: 2010

Journal Articles

Critical Role of Immobilized Factor VIII In Solid-Phase Blood Coagulation During Mural Thrombogenesis Under Whole Blood Flow Conditions

Masaaki Doi, MD, Mitsuhiko Sugimoto, MD, PhD, Hideto Matsui, MD, PhD, Tomoko Matsumoto, Midori Shima, MD, PhD

Blood (2010) 116 (21): 2199.

https://doi.org/10.1182/blood.V116.21.2199.2199

Published: 2010

Journal Articles

Determination for Coagulation Functions and Novel Inhibitory Mechanisms in Acquired Hemophilia A with Type 2 Inhibitors.

Tomoko Matsumoto, Keiji Nogami, Kenichi Ogiwara, Katsumi Nishiya, Masahiro Takeyama, Midori Shima

Blood (2009) 114 (22): 3483.

https://doi.org/10.1182/blood.V114.22.3483.3483

Published: 2009

Journal Articles

Mechanisms of Human Neutrophil Elastase-Catalyzed Inactivation of the Factor VIII(a).

Katsumi Nishiya, Keiji Nogami, Tomoko Matsumoto, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima

Blood (2009) 114 (22): 2125.

https://doi.org/10.1182/blood.V114.22.2125.2125

Published: 2009

NARROW

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)

Anti-Factor IXa/Factor X Antibody (ACE910) Improves the Coagulation Function in Acquired Hemophilia A ex vivo

Activated Protein C-Catalyzed Factor Va Inactivation Predominantly Contributes to the Downregulation of Coagulation Rather Than Factor VIIIa Inactivation

Factor VIII A2 Domain Contains a Binding Site for Factor X

Distinct Localization of Coagulation Factor VIII, Von Willebrand Factor and Factor VIIIa-Mimetic Bispecific Antibody Contributing to Thrombus Formation Under Whole Blood Flow Conditions

Novel FV mutation (W1920R, FV Nara ) associated with serious deep vein thrombosis and more potent APC resistance relative to FV Leiden

An Optimal Monitoring On Bypassing Therapy for Hemophilia A Patients with Inhibitor Using aPTT-Based Clot Waveform Analysis with the Presence of Minimal TF

Coagulation Functions with Clinical Phenotype and Inhibitory Mechanisms in Acquired Factor V Inhibitors.

Total-Thrombus-Formation Analysis System Using a Microchip Flow Chamber Reflects Bleeding Severity of Patients with Type 1 Von Willebrand Disease.

Mechanism of the Potent Activated Protein C Resistance of Novel Factor V Mutation with W1920R (FV Nara) Relative to R506Q (FV Leiden)

Pharmacokinetics of Continuous Infusion Therapy of Factor VIII Concentrates in Hemophilia A Patients with Inhibitors,

Evaluation of Comprehensive Hemostatic Function of Patients with Von Willebrand Disease (VWD) Under Flow Using a New Microchip Flow Chamber System

Determination of Coagulation Functions and Inhibitory Mechanisms In Acquired Hemophilia A with Type 1 and Type 2 Inhibitors.

Critical Role of Immobilized Factor VIII In Solid-Phase Blood Coagulation During Mural Thrombogenesis Under Whole Blood Flow Conditions

Determination for Coagulation Functions and Novel Inhibitory Mechanisms in Acquired Hemophilia A with Type 2 Inhibitors.

Mechanisms of Human Neutrophil Elastase-Catalyzed Inactivation of the Factor VIII(a).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only